Health economic assessment: a methodological primer.

Outcome measurement in economic evaluations of public health interventions: a role for the capability approach? Int J Environ Res Public Health (2010) 1.35

Health economic assessment: cost-effectiveness thresholds and other decision criteria. Int J Environ Res Public Health (2010) 1.03

Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold. Int J Environ Res Public Health (2010) 0.96

Early versus late parenteral nutrition in ICU patients: cost analysis of the EPaNIC trial. Crit Care (2012) 0.89

Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. Health Econ (2016) 0.88

Overview of pharmacoeconomic modelling methods. Br J Clin Pharmacol (2013) 0.84

Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. Clinicoecon Outcomes Res (2012) 0.83

Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria. Balkan Med J (2016) 0.81

Grand challenges in pharmacoeconomics and health outcomes. Front Pharmacol (2010) 0.80

Selective decontamination of the digestive tract and selective oropharyngeal decontamination in intensive care unit patients: a cost-effectiveness analysis. BMJ Open (2013) 0.77

Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy. Subst Abuse Rehabil (2012) 0.76

Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4. Clinicoecon Outcomes Res (2013) 0.75

Maximizing cost-effectiveness by adjusting treatment strategy according to glaucoma severity. Medicine (Baltimore) (2016) 0.75

Is there an economic case for investing in nursing care--what does the literature tell us? J Adv Nurs (2014) 0.75

Are Free Maternity Services Completely Free of Costs? Osong Public Health Res Perspect (2015) 0.75

Histopathological examination of specimen following cholecystectomy: Are we accepting resect and discard? Surg Endosc (2016) 0.75

How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ (1992) 10.40

National Institute for Clinical Excellence and its value judgments. BMJ (2004) 8.97

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health (2003) 6.02

Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health (2005) 5.25

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health (2004) 4.98

Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78

Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ (1994) 4.47

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health (2007) 3.93

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res (2008) 3.50

Modelling in economic evaluation: an unavoidable fact of life. Health Econ (1997) 3.40

Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics (2001) 3.03

The CE plane: a graphic representation of cost-effectiveness. Med Decis Making (1990) 2.93

Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health (2003) 2.61

Endometriosis: cost estimates and methodological perspective. Hum Reprod Update (2007) 2.00

Review of NICE's recommendations, 1999-2005. BMJ (2006) 1.88

Cost-of-illness studies : a review of current methods. Pharmacoeconomics (2006) 1.84

Health technology assessment and priority setting for health policy in Sweden. Int J Technol Assess Health Care (2004) 1.75

Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ (2005) 1.50

Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Rev Pharmacoecon Outcomes Res (2009) 1.47

Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology. Can J Clin Pharmacol (2009) 1.30

What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems. Health Policy (2001) 1.25

Health utility estimation. Expert Rev Pharmacoecon Outcomes Res (2002) 1.23

Methodological issues in the monetary valuation of benefits in healthcare. Expert Rev Pharmacoecon Outcomes Res (2003) 1.13

The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics (2007) 1.02

Cost-effectiveness acceptability curves and a reluctance to lose. Pharmacoeconomics (2005) 1.00

Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology. Drug Alcohol Depend (2006) 0.94

Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics (2005) 0.93

Clinical practice and costs of treating catheter-related infections with teicoplanin or vancomycin. Pharm Pract (Granada) (2006) 0.82

Health economics of market access for biopharmaceuticals and biosimilars. J Med Econ (2009) 0.87

Non-health-care costs associated with endometriosis. Hum Reprod (2011) 0.76

Cardiovascular drug use prior to diagnosis of diabetes: a pilot study in community pharmacy. Int J Pharm Pract (2009) 0.75